<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860652</url>
  </required_header>
  <id_info>
    <org_study_id>TROG 08.03</org_study_id>
    <nct_id>NCT00860652</nct_id>
  </id_info>
  <brief_title>Radiotherapy - Adjuvant Versus Early Salvage</brief_title>
  <acronym>RAVES</acronym>
  <official_title>Radiotherapy - Adjuvant Versus Early Salvage. A Phase III Multi-centre Randomised Trial Comparing Adjuvant Radiotherapy (RT) With Early Salvage RT in Patients With Positive Margins or Extraprostatic Disease Following Radical Prostatectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trans Tasman Radiation Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Urological Society of Australia and New Zealand (USANZ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australian and New Zealand Urogenital and Prostate Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trans Tasman Radiation Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radical prostatectomy (RP) is the most common curative approach offered to men with newly&#xD;
      diagnosed prostate cancer. Unfortunately, up to half of these patients will have factors&#xD;
      placing them at high risk of their cancer recurring. Having radiotherapy after RP is known to&#xD;
      improve cure rates, but what is not known is whether it should be given straight after the&#xD;
      operation or only when there is a rising PSA after surgery indicating active cancer.&#xD;
      Immediate RT may not benefit all men, and can cause serious side effects such as bladder and&#xD;
      bowel problems and impotence. International lack of consensus on the optimal timing of RT has&#xD;
      resulted in varied clinical practice. This phase 3 trial will compare the two approaches.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-centre, international, randomised controlled trial with a 1:1&#xD;
      allocation ratio. Patients with positive margins and/or pT3 disease will be randomised to&#xD;
      adjuvant RT (Standard Arm) or active surveillance with salvage RT delivered at early relapse&#xD;
      (Experimental Arm). 64 Gy in 32 fractions will be delivered to the prostate bed. QoL&#xD;
      self-assessment questionnaires, Hospital Anxiety and Depression Score and toxicity will be&#xD;
      assessed at baseline, the end of RT and annually for 5 years. Patients will be seen by their&#xD;
      doctor 6 monthly for the first 5 years, then annually for the next 5 years. A blood test&#xD;
      measuring prostate specific antigen (PSA) is done 3 monthly for the first 5 years for&#xD;
      patients randomised to early salvage RT, then 6 monthly from years 5 to 10.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 3, 2009</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical failure: PSA ≥ 0.4 ng/ml and rising following RT</measure>
    <time_frame>After 160 events have been observed, expected to be 5 years after recruitment closes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Final Analysis will be after 160 events, estimated to be five years after the end of accrual</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety/Depression</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical failure-free survival</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant failure</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local failure</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the initiation of androgen ablation</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality adjusted life years</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-utility</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Adjuvant Radiotherapy (RT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant Radiotherapy (64Gy in 32 Fractions to the prostate bed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Surveillance with Early SalvageRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Surveillance with Early Salvage Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Adjuvant Radiotherapy</intervention_name>
    <description>Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.</description>
    <arm_group_label>Adjuvant Radiotherapy (RT)</arm_group_label>
    <other_name>ART, Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Early Salvage Radiotherapy</intervention_name>
    <description>Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.</description>
    <arm_group_label>Active Surveillance with Early SalvageRT</arm_group_label>
    <other_name>SRT, Surveillance, Radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior Radical Prostatectomy (RP) for adenocarcinoma of the prostate.&#xD;
&#xD;
          -  Histological confirmation of adenocarcinoma of the prostate with the Gleason score&#xD;
             reported (Radical Prostatectomy specimen).&#xD;
&#xD;
          -  Patients must have at least one of the following risk factors: 1) Positive margins, 2)&#xD;
             Extraprostatic extension (EPE) with or without seminal vesicle involvement (pT3a or&#xD;
             pT3b)&#xD;
&#xD;
          -  Capable of starting RT within 4 months of RP (a requirement if randomised to adjuvant&#xD;
             RT arm)&#xD;
&#xD;
          -  Most recent PSA ≤ 0.10 ng/ml following RP and prior to randomisation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1&#xD;
&#xD;
          -  Patient able to adhere to the specified follow-up schedule and complete the Quality of&#xD;
             Life and anxiety/depression self-assessments&#xD;
&#xD;
          -  Written informed consent obtained prior to randomisation&#xD;
&#xD;
          -  Completion of all pre-treatment evaluations&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous pelvic RT&#xD;
&#xD;
          -  Androgen deprivation (AD) prior to or following RP&#xD;
&#xD;
          -  Evidence of nodal or distant metastases&#xD;
&#xD;
          -  Co-morbidities that would interfere with the completion of treatment and/or 5 years of&#xD;
             follow-up&#xD;
&#xD;
          -  Concurrent cytotoxic medication&#xD;
&#xD;
          -  Hip prosthesis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Pearse, MBChB</last_name>
    <role>Study Chair</role>
    <affiliation>Trans Tasman Radiation Oncology Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Kneebone</last_name>
    <role>Study Chair</role>
    <affiliation>Trans Tasman Radiation Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Campbelltown Hopsital</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coffs Harbour Health Campus, NCCI</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Associates</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Clinic</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>1871</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2310</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central West Cancer Services (Orange Health)</name>
      <address>
        <city>Orange</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Port Macquarie Base Hospital, NCCI</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverina Cancer Care Centre</name>
      <address>
        <city>Wagga Wagga</city>
        <state>New South Wales</state>
        <zip>2650</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Adventist Hospital</name>
      <address>
        <city>Wahroonga</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Gold Coast</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oceania Oncology</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology - Mater Centre</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toowoomba Cancer Research Centre</name>
      <address>
        <city>Toowoomba</city>
        <state>Queensland</state>
        <zip>4350</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premion</name>
      <address>
        <city>Tugun</city>
        <state>Queensland</state>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred/WBRC</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perth Radiation Oncology</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6014</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Radiation Oncology</name>
      <address>
        <city>Epsom</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Newtown</city>
        <state>Wellington</state>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <zip>9016</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmerston North Hospital</name>
      <address>
        <city>Palmerston North</city>
        <zip>4414</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>http://www.trog.com.au</url>
    <description>Trans Tasman Radiation Oncology Group</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oncology</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Radical Prostatectomy</keyword>
  <keyword>Prior Radical Prostatectomy (RP)</keyword>
  <keyword>Histological Confirmation of adenocarcinoma of the prostate</keyword>
  <keyword>Positive margins and/or extraprostatic extension (EPE)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

